

Mouse Kallikrein 7/KLK7 Protein (active form)

Cat. No. KLK-MM107

Description

Source	Recombinant Mouse Kallikrein 7/KLK7 Protein (active form) is expressed from HEK293 with His tag at the C-terminus.
	It contains Ile26-Arg249.
Accession	Q91VE3
Molecular Weight	The protein has a predicted MW of 26.21 kDa. Due to glycosylation, the protein migrates to 30-40 kDa based on Bis-Tris PAGE result.
Endotoxin	Less than 0.1 EU per µg by the LAL method.
Purity	> 90% as determined by Bis-Tris PAGE

Formulation and Storage


Formulation	Lyophilized from 0.22 µm filtered solution in 20mM NaAC, 150mM NaCl, 8% trehalose, 0.05% Brij-35, 5mM Benzamidine (pH 5.0).
Reconstitution	Dissolve the lyophilized protein in 20mM NaAC (pH 5.0). Please refer to the Certificate of Analysis for detailed instructions.
Storage	-20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Background

Kallikrein 7 (KLK7) is a secreted serine protease with chymotrypsic protease activity. Abnormally high expression of KLK7 is closely related to the occurrence and development of various types of cancer. Therefore, KLK7 has been identified as a potential target for cancer drug development design in recent years. KLK7 mediates various biological and pathological processes in tumorigenesis, including cell proliferation, migration, invasion, angiogenesis, and cell metabolism, by hydrolyzing a series of substrates such as membrane proteins, extracellular matrix proteins, and cytokines.

Assay Data

Bis-Tris PAGE



Mouse Kallikrein 7 on Bis-Tris PAGE under reduced condition. The purity is greater than 90%.

Bioactivity Data

Measured by its ability to cleave the fluorogenic peptide substrate, Mca-RPKPVE-Nval-WRK(Dnp)-NH₂. The specific activity is >300 pmol/min/µg.